GlaxoSmithKline Merger Completion Delayed To Year-End
This article was originally published in The Tan Sheet
Executive Summary
The planned merger of SmithKline Beecham and Glaxo Wellcome will be delayed, likely until the end of the year, due to continued Federal Trade Commission inquiries.
You may also be interested in...
NiQuitin CQ Smoking Cessation Lozenge Could Be On U.S. Shelves By Year-End
GlaxoSmithKline has submitted an NDA for its NiQuitin CQ lozenges and could receive FDA approval before the end of the year, the firm said
NiQuitin CQ Smoking Cessation Lozenge Could Be On U.S. Shelves By Year-End
GlaxoSmithKline has submitted an NDA for its NiQuitin CQ lozenges and could receive FDA approval before the end of the year, the firm said
NiQuitin CQ Smoking Cessation Lozenge Could Be On U.S. Shelves By Year-End
GlaxoSmithKline has submitted an NDA for its NiQuitin CQ lozenges and could receive FDA approval before the end of the year, the firm said